Allarity Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Allarity Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.81M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($2.32M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.32M) | Aug 15, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.73M) | May 9, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.73M) | Aug 15, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.73M) | Nov 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($11.59M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($1.63M) | Aug 15, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($1.63M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.84M) | May 9, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($3.84M) | Aug 15, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($3.84M) | Nov 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.45M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($2.38M) | Aug 5, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($2.38M) | Nov 14, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($3.35M) | Aug 5, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($3.35M) | May 14, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($3.35M) | Nov 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($5.04M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($5.10M) | Nov 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.52M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.13M) | Aug 15, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($3.04M) | May 9, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($12.31M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($3.37M) | Aug 15, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($4.24M) | May 9, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.43M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.16M) | Aug 5, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($3.67M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($4.56M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($4.84M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($18.31M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($3.97M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($4.38M) | Oct 7, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($2.46M) | May 27, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($1.74M) | May 17, 2022 |